



GlaxoSmithKline Investing in Oklahoma

GlaxoSmithKline (GSK) is a world-leading research-based pharmaceutical company whose mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Operations of GSK circle the globe and address a common purpose: providing innovative medicines and services that prevent and treat disease. True to that mission, GSK scientists and other employees are searching for new and better treatments for a variety of diseases. GSK's research and development expenditures worldwide total \$5.6 billion annually. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products, and nutritional health products, all of which are among the market leaders. GSK has US headquarters in Philadelphia, PA and Research Triangle Park, NC as well as employees in all 50 states.

Being a good corporate citizen is one of GSK's key priorities. Committed to the communities in which we work around the country, our charitable and community programs support projects that are innovative, sustainable, and focused on producing tangible results. GSK will continue to build on these foundations of wide-ranging philanthropic support, which reflects its position as one of the largest research-based pharmaceutical companies in the world.

ECONOMIC CONTRIBUTIONS IN OKLAHOMA

Clinical Grants	\$1,600,318
Patient Assistance Program	\$8,946,243
Corporate Contributions	\$344,585
Taxes Paid	\$263,440
Total Business Expenditures*	\$27,966,701

EMPLOYMENT

Oklahoma	121
United States	24,947
Worldwide	110,000

WORLDWIDE RESEARCH AND DEVELOPMENT INVESTMENTS

\$5.6 billion annually

PHARMACEUTICAL AREAS

Anti-infectives	Depression
Asthma	Diabetes
Cancer	HIV-AIDS
Cardiovascular	Migraine
COPD	Osteoporosis

VACCINES

DTaP	Influenza
Hepatitis A	Polio
Hepatitis B	Tdap

CONSUMER HEALTHCARE AREAS

Dermatology	Gastrointestinal
Nutrition	Oral Health
Smoking Cessation	Vitamins & Naturals

*Includes rebates, employee costs, and other business expenses

All figures are for 2005.